Neratinib has been confirmed to be effective in extended adjuvant therapy following trastuzumab for HER2-positive early BC in the ExteNET trial(Chan et al. 2021; Harbeck 2022; Martin et al. 2017; Singh et al. 2018). This evidence concerns the gene ERBB2 and breast cancer.